Literature DB >> 28692030

HLA-mismatched bone marrow transplantation in severe aplastic anemia.

L S Bachegowda1, M V Shah1, L W Veltri1, A Tanase2, U Popat1, P Anderlini1, J Chen1, G Rondon1, R E Champlin1, S O Ciurea1.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28692030      PMCID： PMC7232775          DOI： 10.1038/bmt.2017.146

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  9 in total

Review 1.  Bone marrow transplantation for severe aplastic anemia from HLA identical siblings.

Authors:  A Bacigalupo
Journal:  Haematologica       Date:  1999-01       Impact factor: 9.941

2.  Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.

Authors:  Sameh Gaballa; Isabell Ge; Riad El Fakih; Jonathan E Brammer; Piyanuch Kongtim; Ciprian Tomuleasa; Sa A Wang; Dean Lee; Demetrios Petropoulos; Kai Cao; Gabriela Rondon; Julianne Chen; Aimee Hammerstrom; Lindsey Lombardi; Gheath Alatrash; Martin Korbling; Betul Oran; Partow Kebriaei; Sairah Ahmed; Nina Shah; Katayoun Rezvani; David Marin; Qaiser Bashir; Amin Alousi; Yago Nieto; Muzaffar Qazilbash; Chitra Hosing; Uday Popat; Elizabeth J Shpall; Issa Khouri; Richard E Champlin; Stefan O Ciurea
Journal:  Cancer       Date:  2016-07-12       Impact factor: 6.860

Review 3.  Management of the refractory aplastic anemia patient: what are the options?

Authors:  Judith C W Marsh; Austin G Kulasekararaj
Journal:  Blood       Date:  2013-09-19       Impact factor: 22.113

4.  Alternative Donor Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Refractory Severe Aplastic Anemia.

Authors:  Amy E DeZern; Marianna Zahurak; Heather Symons; Kenneth Cooke; Richard J Jones; Robert A Brodsky
Journal:  Biol Blood Marrow Transplant       Date:  2016-12-21       Impact factor: 5.742

5.  Haploidentical BMT and post-transplant Cy for severe aplastic anemia: a multicenter retrospective study.

Authors:  I Esteves; C Bonfim; R Pasquini; V Funke; N F Pereira; V Rocha; Y Novis; C Arrais; V Colturato; M P de Souza; M Torres; J F Fernandes; F R Kerbauy; A A F Ribeiro; F P S Santos; N Hamerschlak
Journal:  Bone Marrow Transplant       Date:  2015-03-02       Impact factor: 5.483

6.  HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry.

Authors:  Loren Gragert; Mary Eapen; Eric Williams; John Freeman; Stephen Spellman; Robert Baitty; Robert Hartzman; J Douglas Rizzo; Mary Horowitz; Dennis Confer; Martin Maiers
Journal:  N Engl J Med       Date:  2014-07-24       Impact factor: 91.245

7.  HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.

Authors:  Leo Luznik; Paul V O'Donnell; Heather J Symons; Allen R Chen; M Susan Leffell; Marianna Zahurak; Ted A Gooley; Steve Piantadosi; Michele Kaup; Richard F Ambinder; Carol Ann Huff; William Matsui; Javier Bolaños-Meade; Ivan Borrello; Jonathan D Powell; Elizabeth Harrington; Sandy Warnock; Mary Flowers; Robert A Brodsky; Brenda M Sandmaier; Rainer F Storb; Richard J Jones; Ephraim J Fuchs
Journal:  Biol Blood Marrow Transplant       Date:  2008-06       Impact factor: 5.742

8.  Nonmyeloablative peripheral blood haploidentical stem cell transplantation for refractory severe aplastic anemia.

Authors:  Jennifer Clay; Austin G Kulasekararaj; Victoria Potter; Francesco Grimaldi; Donal McLornan; Kavita Raj; Hugues de Lavallade; Michelle Kenyon; Antonio Pagliuca; Ghulam J Mufti; Judith C W Marsh
Journal:  Biol Blood Marrow Transplant       Date:  2014-07-10       Impact factor: 5.742

9.  Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation.

Authors:  Stefan O Ciurea; Victor Mulanovich; Rima M Saliba; Ulas D Bayraktar; Ying Jiang; Roland Bassett; Sa A Wang; Marina Konopleva; Marcelo Fernandez-Vina; Nivia Montes; Doyle Bosque; Julianne Chen; Gabriela Rondon; Gheath Alatrash; Amin Alousi; Qaiser Bashir; Martin Korbling; Muzaffar Qazilbash; Simrit Parmar; Elizabeth Shpall; Yago Nieto; Chitra Hosing; Partow Kebriaei; Issa Khouri; Uday Popat; Marcos de Lima; Richard E Champlin
Journal:  Biol Blood Marrow Transplant       Date:  2012-07-11       Impact factor: 5.742
  9 in total
  1 in total

1.  Posttransplant cyclophosphamide in allogeneic bone marrow transplantation for the treatment of nonmalignant hematological diseases.

Authors:  Mark Leick; Bradley Hunter; Zachariah DeFilipp; Bimalangshu R Dey; Areej El-Jawahri; Matthew Frigault; Steven McAfee; Thomas R Spitzer; Paul O'Donnell; Yi-Bin Chen
Journal:  Bone Marrow Transplant       Date:  2019-10-24       Impact factor: 5.483
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.